+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
KOPRAN

Kopran Share Price

 

 

Kopran live price: ₹193.31. It opened at ₹186 vs previous close ₹188; intraday high/low: ₹195/₹186. The 50 & 200 DMA stand at ₹176.68/₹162.34.

Kopran Performance

  • Today's Low
  • ₹186
  • Today's High
  • ₹195
  • 52 Week Low
  • ₹107
  • 52 Week High
  • ₹219
  • Open Price₹186
  • Previous Close₹188
  • Volume146,623
  • 50 DMA₹176.68
  • 100 DMA₹165.00
  • 200 DMA₹162.34

Kopran Chart

Investment Returns

  • Over 1 Month -1.33%
  • Over 3 Month + 61.12%
  • Over 6 Month + 27.11%
  • Over 1 Year + 4.84%

Smart Investing Starts Here Start SIP with Kopran for Steady Growth!

Invest Now

Kopran Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 36.3
  • PEG Ratio
  • -1.1
  • Market Cap Cr
  • 933
  • P/B Ratio
  • 1.8
  • Average True Range
  • 9.32
  • EPS
  • 5.33
  • Dividend Yield
  • 1.6
  • MACD Signal
  • 4.96
  • RSI
  • 57.42
  • MFI
  • 55.19

Latest Stock News Updates

Kopran Consolidated December 2023 Net Sales at Rs 158.92 crore, up 0.58% Y-o-Y

Kopran Standalone September 2023 Net Sales at Rs 98.64 crore, up 83.95% Y-o-Y

Kopran Consolidated March 2023 Net Sales at Rs 148.88 crore, up 4.95% Y-o-Y

Kopran Financials

Kopran Technicals

EMA & SMA

Current Price
₹193.31
+ 5.47 (2.91%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹187.80
  • 50 Day
  • ₹176.70
  • 100 Day
  • ₹165.00
  • 200 Day
  • ₹162.30

Resistance and Support

191.47 Pivot Speed
  • R3 205.74
  • R2 200.37
  • R1 196.84
  • S1 187.94
  • S2 182.57
  • S3 179.04

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kopran Ltd. is a fully integrated pharmaceutical company, engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company serves global markets with a focus on innovation, quality, and regulatory compliance.

Kopran has an operating revenue of Rs. 683.82 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 5% is okay, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 23% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Kopran Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-19 Audited Results & Final Dividend
2026-01-22 Quarterly Results
2025-11-12 Quarterly Results
2025-07-29 Quarterly Results
2025-05-15 Audited Results & Final Dividend
Date Purpose Remarks
2025-09-04 FINAL Rs.3.00 per share(30%)Final Dividend
View Kopran Dividend History Arrow

Kopran Shareholding Pattern

44.42%
0%
0.57%
0%
44.08%
10.93%

Kopran FAQs

Kopran share price is ₹193 As on 03 July, 2026 | 23:42

The Market Cap of Kopran is ₹933.4 Cr As on 03 July, 2026 | 23:42

The P/E ratio of Kopran is 36.3 As on 03 July, 2026 | 23:42

The PB ratio of Kopran is 1.8 As on 03 July, 2026 | 23:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23